mariam zaghloul | Kafrelsheikh University (original) (raw)

Papers by mariam zaghloul

Gastrointestinal endoscopy, Jun 1, 2024

Beni-Seuf University Journal of Basic and Applied Sciences /Beni-Suef University Journal of Basic and Applied Sciences, May 7, 2024

Background Liver cancer (hepatocellular carcinoma "HCC") remains a significant health issue witho... more Background Liver cancer (hepatocellular carcinoma "HCC") remains a significant health issue without prompt detection and appropriate prevention. By interacting with each other, long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) can form gene regulatory networks. Specifically, we aim to determine whether the lncRNAs (HOTTIP, H19, and HOTAIR) and miRNA-152 interact in a significant manner in the progression of Hepatitis C virus (HCV) patients to HCC. This is followed by the question of whether these biomarkers can be used to diagnose and prognose noninvasively. We used online computational techniques to predict which miRNA group is likely to affect the lncRNAs being examined. This study involved 133 participants. 103 patients with HCV were included in the study, which was divided into two groups: Group I, with 65 cases of chronic liver disease without HCC, and Group II, with 38 cases of chronic liver disease with HCC. In addition, 30 healthy volunteers served as controls. In this study, a qRT-PCR was used to test gene expression. Results A consistent reverse correlation has been observed between lncRNAs and miRNA-152 as the disease progresses. Conclusion According to our findings, the studied biomarkers may be useful as noninvasive biomarkers for prognosis in patients with HCV Genotype 4 who develop liver cirrhosis and HCC. Many miRNAs, including miRNA-19a and miRNA-106a, may interact with lncRNAs that have been investigated in addition to miRNA-152.

World journal of gastroenterology, Mar 28, 2024

International Journal of Cancer and Biomedical Research, Mar 1, 2024

Journal of Pakistan Medical Association, May 25, 2023

Objectives: To assess left ventricular functions by echocardiography after 12 weeks of sofosbuvir... more Objectives: To assess left ventricular functions by echocardiography after 12 weeks of sofosbuvir-daclatasvir combination therapy. Method: The prospective cohort study was conducted from December 2019 to December 2021 at Kafrelsheikh University Hospital, Egypt, and comprised adult patients of either gender who had been referred to the Cardiovascular Department for cardiac evaluation and were found to be eligible for sofosbuvir-daclatasvir combination therapy. The patients were classified into five groups according to cardiovascular risk factors. Group 1 had no risk factors; Group 2 had many risk factors; Group 3 had only hypertension; Group 4 had diabetes only; and Group 5 had smoking as the only risk. All patients were assessed at baseline and at the end of the 12-week of antiviral combination therapy sofosbuvir 400 mg once daily dose and daclatasvir 60 mg once daily dose. Parameters checked were left ventricular ejection fraction, global longitudinal strain, wall motion abnormalities and diastolic function. Data was analysed using SPSS 23. Results: Of the 200 patients, 104(52%) were females and 96(48%) were males. The age range was 34-81 years, and 18(9%) patients were aged >70 years. There were 78(39%) patients in Group 1, 60(30%) in Group 2, 25(12.5%) in Group 3, Group 4 had 13(6.5%) and Group 5 had 24(12%) patients. There were no significant changes in mean ejection fraction, global longitudinal strain and wall motion abnormalities (p>0.05). Diastolic function had some significant parameters in each of the 5 groups (p<0.05). Conclusion: Sofosbuvir-daclatasvir combination therapy did not affect or impair left ventricular systolic or diastolic functions.

Egyptian Liver Journal, Feb 17, 2022

Background/aims: We prospectively evaluated the role of endoscopic ultrasound (EUS) in detecting ... more Background/aims: We prospectively evaluated the role of endoscopic ultrasound (EUS) in detecting the cause of common bile duct (CBD) dilatation in patients in whom trans-abdominal ultrasound (TUS) could not demonstrate the cause of dilation as a proper second step in the diagnostic workup of patients with obstructive jaundice compared to magnetic resonance cholangiopancreatography (MRCP). Methods: This study was conducted on patients with obstructive jaundice admitted to the inpatient ward or the outpatient endoscopy unit of Theodor Bilharz Research Institute (TBRI) during the period between January 2019 and August 2019. A patient with obstructive jaundice and TUS showed CBD dilatation with internal diameter ≥ 7 mm and biliary stricture. Results: During the period between January 2019 and August 2019, 136 were recruited; 8 patients who were pregnant and 3 patients who had gastric bypass surgery were excluded. Sixty-five patients were diagnosed confidently by TUS as biliary stones and were excluded from the analysis. Sixty patients with obstructive jaundice and indefinite etiology on TUS were included in the final analysis. The final diagnosis of patients was 38 patients (63.33%) of malignant etiology [26 pancreatic cancer (43.33%), 4 cholangiocarcinoma (6.66%), and 8 with ampullary cancer (13.33%)] and 22 patients (36.67%) of benign etiology [10 calcular obstruction (16.66%), 8 benign stricture (13.33%), and 4 pancreatitis (6.66%)]. The sensitivity and specificity values for malignant stricture detected by EUS were 100% and 86.36%, respectively, with positive predictive value of 92.68%, negative predictive value of 100%, and accuracy of 95%, while MRI showed 82.14% sensitivity and 25% specificity with positive predictive value of 79.31 and accuracy of 69.4%. EUS supported correct diagnosis in 57 patients (95%: CI 86.08 to 98.96%) while MRI did it in 36 patients (69.44%: CI 51.89% to 83.65%).Only 43 (71.7%) patients needed endoscopic retrograde cholangiopancreatography (ERCP) for management of obstructive jaundice, sparing 17 patients (28.3%) unnecessary invasive procedures. Conclusions: EUS is a minimally invasive method with low incidence of complications with high diagnostic accuracy in patients with dilated CBD and normal MRCP.

The Open Biomarkers Journal, Jul 3, 2020

Background & Aims: Several studies, in different populations, have focused on the role of HLA-DQ ... more Background & Aims: Several studies, in different populations, have focused on the role of HLA-DQ gene polymorphism in the pathogenesis of HBV infection. However, these findings are still controversial. This study aimed to determine HLA-DQ polymorphism in Chronic HBV patients and its impact on the response to antiviral therapy. Methods: This study was carried out on a total number of 188 participants, they were subdivided as follows: Group I (patients' group): included 97 patients with chronic hepatitis B viral infection that was further subdivided according to response to treatment into responder and non-responder subgroups, Group II (Control group): included 91 normal healthy subjects who were matched to the patient group by sex and age. PCR (Polymerase Chain Reaction) testing, for HBV-DNA, was done for all participants enrolled in the study to measure the viral virus load before and after treatment. HLA-DQ polymorphism allelic discrimination assay was assayed using the Real-time equipment. Results: In a general analysis for the SNP rs7453920, the overall genotypes frequencies were 37% for A/A, 60.6% for A/G, and 37% for G/G. The G alleles of HLA-DQ rs7453920 were significantly increased in chronic HBV infection patients. A total of 77 (79.4%) patients were responders. Among this group, 72.7% were male, and the average age was 38.59 ±9.15 years. On evaluation of the association between polymorphisms in HLA-DQ gene and treatment response, the results indicated that response to treatment declined when patients were carrying the more unfavorable rs 7453920 GG with a response rate of 64%. Patients carrying the mutant allele AG, or the wild type allele AA were more likely to achieve a higher rate of response (84.8% and 83.3%, respectively). Conclusion: The presence of HLA-DQB2 rs 7453920-G serves as a risk factor for chronic HBV infection and treatment failure in the Egyptian population.

Iranian Journal of Parasitology

Background: Giardia duodenalis and Blastocystis hominis are among the most common intestinal prot... more Background: Giardia duodenalis and Blastocystis hominis are among the most common intestinal protozoa worldwide. Treatment of infection by metronidazole (MTZ) has some limitations. The objective of this study was to detect the prevalence of Blastocystis and giardiasis among school-age children from December 2021 till March 2022 from Motoubes, Kafrelsheikh, Egypt, and determine the efficacy of nitazoxanide (NTZ), NTZ plus garlic and tinidazole (TIN) on Blastocystis and giardiasis infection. Methods: Stool samples were collected from 390 children and microscopically examined using formalin-ethyl acetate concentration and culturing on Jones' medium for B. hominis. Those who tested positive for giardiasis (120 children, 30.7%) (Group I) or Blastocystis (180 children, 46.1%) (Group II) were equally divided into four subgroups. The first subgroup received NTZ orally, every 12 hours for three successive days. The second subgroup received NTZ in the same dose as the first subgroup plus ...

Gastroenterology, 2003

BACKGROUND: Endoscopic ultrasound and fine-needle aspiration (EUS-FNA) has gained wide acceptance... more BACKGROUND: Endoscopic ultrasound and fine-needle aspiration (EUS-FNA) has gained wide acceptance as a modality for the diagnosis and staging of pancreatic cancer. EUS-FNA has also recemly been reported to differentiate benign from malignant cystic lesions of the pancreas. The aim of this study is to establish the accuracy of EUS-FNA in diagnosing cystic lesions when compared to surgical pathology. METHOD: We retrospecnvely analyzed all patients who underwent EUS-FNA of a cystic pancreatic lesion from 10/99 9/02. A positive FNA result was defined by the presence of adenocarcinoma or mucin; cytology reported as highly suspicious for adenocarcinoma was also considered positive. Cyst fluid CEA levels were defined as consistent with malignancy if greater than 500 units/ml. Cyst fluid amylase levels were defined as consistent with a benign inflammatory pseudocyst if greater than 5000 IU/L. RESULTS: EUS-FNA was performed on 84 patients with a mean age of 58.9 years. 63% were female patients. Fluid and mucnions material was successfully aspirated from the pancreatic cyst in 73 patients. 24 of the 73 patients underwent surgical resection of the pancreas. 15 of the 24 surgical patients were found to have adenocarcinoma or a mucinous neoplasm on final histopathology of the surgical specimen. 14 (93%) of the 15 patients were correctly diagnosed preoperatively by EUS-FNA. 9 of the 24 patients were found to have a nonmalignant diagnosis on final histopathology of the surgical specimen. 3 (30%) were correctly diagnosed either as serous cystadenomas (1) or inflammatory pseudocysts (2). 49 of 73 patients did not undergo surgery. EUS-FNA was positive in 21 of these patients; surgery was not performed because of medical co-mothidities, metastatic disease "or local tumor unresectability. Clinical follow-up supported advanced cancer in all 2t patients. EUS-FNA suggested benign disease in 28 of the 49 patients; clinical and radiographic follow-up has failed to demonstrate invasive cancer in any of these 28 patients. CONCLUSION: EUS-FNA of pancreatic cystic lesions is an accurate technique for the differentiation of benign and malignant disease. It is the diagnostic procedure of choice in those patients who require a cytological diagnosis of malignancy to allow the delivery of chemotherapy or in patients with presumed benign disease (serous cystadenoma or pseudocyst) in whom observation is most appropriate.

World Journal of Hepatology, Feb 27, 2023

World Journal of Clinical Cases

World Journal of Methodology

Infection and Drug Resistance, May 1, 2022

Background and Aim: Little is known about the persistence of symptoms after clearance of SARS-CoV... more Background and Aim: Little is known about the persistence of symptoms after clearance of SARS-CoV-2 infection. Our study aimed to assess persistent symptoms in COVID-19 patients after clearance of SARS-CoV-2 infection. Methodology: A multi-center survey was conducted on first wave COVID-19 patients with confirmed SARS-CoV-2 infection. Sociodemographic and clinical characteristics, including presenting symptoms and persistent symptoms after viral clearance and possible factors contributing to persistence of such symptoms, were collected using an online multicomponent questionnaire. Descriptive and inferential statistical analysis was performed to detect the most persisting symptoms and factors contributing to their persistence. Results: Overall, 538 patients were enrolled. Mean age was 41.17 (±SD 14.84), 54.1% were males, and 18.6% were smokers. Hypertension and diabetes were the most reported co-morbidities. Mild symptoms were reported in 61.3% of patients, 51.3% were admitted to hospital and 6.5% were admitted to the intensive care unit. Our study identified 49 types of persisting symptoms. Fatigue (59.1%), sense of fever (46.5%), anorexia (24.3%) and diarrhea (24.3%) were the most commonly reported persisting symptoms followed by loss of taste and smell (22.3%), headache (21.4%), cough (20.8) and dyspnea (21%). The use of hydroxychloroquine, azithromycin and multivitamins were significantly associated with persistence of symptoms (OR = 8.03, 8.89 and 10.12, respectively). Conclusion: Our study revealed that in COVID-19 recovered patients, many patients reported persistence of at least one symptom, particularly fatigue and sense of fever. Follow-up of patients after discharge from hospital is recommended until complete resolution of symptoms.

Journal of Hepatology, 2018

Background and Aims: Malignant hepatic epithelioid hemangioendothelioma (HEH) is a rare malignant... more Background and Aims: Malignant hepatic epithelioid hemangioendothelioma (HEH) is a rare malignant tumor of vascular origin with unknown etiology and a variable natural course. This study evaluated the current management and prognosis of HEH status based on SEER data analysis from 1973 to 2007. Method: Using SEER database, a total 79 patients with HEH were analyzed from 1973 to 2014. Patient survival was calculated using Kaplan-Meier survival curves with log rank test. Results: The mean age of patients with HEH was 53.0 years, and the male to female ratio was 1:2.6. About one third (40.8%) of patients were diagnosed at regional metastatic stage followed by local (30.3%) and distant metastatic stage (28.9%). Median tumor size was 3.85cm (IQR, 2.50-7.93cm). Thirty four (43.0%) of patients received no treatment or the treatment information was missing. Of the 45 treated patients, the most common treatment was chemotherapy (48.9%) followed by resection (22.2%). About 22.2% of patients were treated with more than one method. The 1-year and 5-year survival rates were 88% and 88%, respectively in resection or liver transplantation group; 72% and 49%, respectively in other treatment or observation group. Resection or liver transplantation based treatment was only independent predictive factor for survival (hazard ratio 0.17, 95% confidence interval 0.04-0.75, P = 0.020). Conclusion: Resection or liver transplantation is worth considering for treatment of patients with HEH.